MoeS, DrüekeT, CunninghamJ, GoodmanW, MartinK, OlgaardK,
et al.
.; Kidney Disease: Improving Global Outcomes (KDIGO): Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int69: 1945–1953, 2006PubMed
MoeS, DrüekeT, CunninghamJ, GoodmanW, MartinK, OlgaardK, .; Kidney Disease: Improving Global Outcomes (KDIGO): Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int69: 1945–1953, 2006PubMed10.1038/sj.ki.5000414)| false
CozzolinoM, Ureña-TorresP, VervloetMG, BrandenburgV, BoverJ, GoldsmithD,
et al.
.; CKD-MBD Working Group of ERA-EDTA: Is chronic kidney disease-mineral bone disorder (CKD-MBD) really a syndrome?Nephrol Dial Transplant29: 1815–1820, 2014PubMed
CozzolinoM, Ureña-TorresP, VervloetMG, BrandenburgV, BoverJ, GoldsmithD, .; CKD-MBD Working Group of ERA-EDTA: Is chronic kidney disease-mineral bone disorder (CKD-MBD) really a syndrome?Nephrol Dial Transplant29: 1815–1820, 2014PubMed10.1093/ndt/gft514)| false
HillegeHL, FidlerV, DiercksGF, van GilstWH, de ZeeuwD, van VeldhuisenDJ,
et al.
.; Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group: Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation106: 1777–1782, 2002PubMed
HillegeHL, FidlerV, DiercksGF, van GilstWH, de ZeeuwD, van VeldhuisenDJ, .; Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group: Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation106: 1777–1782, 2002PubMed10.1161/01.CIR.0000031732.78052.81)| false
FeldreichT, NowakC, CarlssonAC, ÖstgrenCJ, NyströmFH, SundströmJ,
et al.
: The association between plasma proteomics and incident cardiovascular disease identifies MMP-12 as a promising cardiovascular risk marker in patients with chronic kidney disease. Atherosclerosis307: 11–15, 2020PubMed
FeldreichT, NowakC, CarlssonAC, ÖstgrenCJ, NyströmFH, SundströmJ, : The association between plasma proteomics and incident cardiovascular disease identifies MMP-12 as a promising cardiovascular risk marker in patients with chronic kidney disease. Atherosclerosis307: 11–15, 2020PubMed10.1016/j.atherosclerosis.2020.06.013)| false
MeijersB, JouretF, EvenepoelP: Linking gut microbiota to cardiovascular disease and hypertension: Lessons from chronic kidney disease. Pharmacol Res133: 101–107, 2018PubMed
van BommelEJ, MuskietMH, TonneijckL, KramerMH, NieuwdorpM, van RaalteDH: SGLT2 inhibition in the diabetic kidney: From mechanisms to clinical outcome. Clin J Am Soc Nephrol12: 700–710, 2017PubMed
van BommelEJ, MuskietMH, TonneijckL, KramerMH, NieuwdorpM, van RaalteDH: SGLT2 inhibition in the diabetic kidney: From mechanisms to clinical outcome. Clin J Am Soc Nephrol12: 700–710, 2017PubMed10.2215/CJN.06080616)| false
WilsonLM, RebholzCM, JirruE, LiuMC, ZhangA, GayleardJ,
et al.
: Benefits and harms of osteoporosis medications in patients with chronic kidney disease: A systematic review and meta-analysis. Ann Intern Med166: 649–658, 2017PubMed
WilsonLM, RebholzCM, JirruE, LiuMC, ZhangA, GayleardJ, : Benefits and harms of osteoporosis medications in patients with chronic kidney disease: A systematic review and meta-analysis. Ann Intern Med166: 649–658, 2017PubMed10.7326/M16-2752)| false
Bouma-de KrijgerA, VervloetMG: Fibroblast growth factor 23: Are we ready to use it in clinical practice?J Nephrol33: 509–527, 2020PubMed10.1007/s40620-020-00715-2)| false
MarthiA, DonovanK, HaynesR, WheelerDC, BaigentC, RooneyCM,
et al.
: Fibroblast growth factor-23 and risks of cardiovascular and noncardiovascular diseases: A meta-analysis. J Am Soc Nephrol29: 2015–2027, 2018PubMed
GraciolliFG, NevesKR, BarretoF, BarretoDV, Dos ReisLM, CanzianiME,
et al.
: The complexity of chronic kidney disease-mineral and bone disorder across stages of chronic kidney disease. Kidney Int91: 1436–1446, 2017PubMed
GraciolliFG, NevesKR, BarretoF, BarretoDV, Dos ReisLM, CanzianiME, : The complexity of chronic kidney disease-mineral and bone disorder across stages of chronic kidney disease. Kidney Int91: 1436–1446, 2017PubMed10.1016/j.kint.2016.12.029)| false
WilliamsMJ, SugataniT, AgapovaOA, FangY, GautJP, FaugereMC,
et al.
: The activin receptor is stimulated in the skeleton, vasculature, heart, and kidney during chronic kidney disease. Kidney Int93: 147–158, 2018PubMed
WilliamsMJ, SugataniT, AgapovaOA, FangY, GautJP, FaugereMC, : The activin receptor is stimulated in the skeleton, vasculature, heart, and kidney during chronic kidney disease. Kidney Int93: 147–158, 2018PubMed10.1016/j.kint.2017.06.016)| false
de BaaijJH, HoenderopJG, BindelsRJ: Regulation of magnesium balance: Lessons learned from human genetic disease. Clin Kidney J5[Suppl 1]: i15–i24, 2012PubMed
CastiglioniS, CazzanigaA, AlbisettiW, MaierJA: Magnesium and osteoporosis: Current state of knowledge and future research directions. Nutrients5: 3022–3033, 2013PubMed
CastiglioniS, CazzanigaA, AlbisettiW, MaierJA: Magnesium and osteoporosis: Current state of knowledge and future research directions. Nutrients5: 3022–3033, 2013PubMed10.3390/nu5083022)| false
ChangJ, YuD, JiJ, WangN, YuS, YuB: The association between the concentration of serum magnesium and postmenopausal osteoporosis. Front Med (Lausanne)7: 381, 2020PubMed
ChangJ, YuD, JiJ, WangN, YuS, YuB: The association between the concentration of serum magnesium and postmenopausal osteoporosis. Front Med (Lausanne)7: 381, 2020PubMed10.3389/fmed.2020.00381)| false
KettelerM, BlockGA, EvenepoelP, FukagawaM, HerzogCA, McCannL,
et al.
: Executive summary of the 2017 KDIGO chronic kidney disease-mineral and bone disorder (CKD-MBD) guideline update: What’s changed and why it matters. Kidney Int92: 26–36, 2017PubMed
SakaguchiY, HamanoT, WadaA, HoshinoJ, MasakaneI: Magnesium and risk of hip fracture among patients undergoing hemodialysis. J Am Soc Nephrol29: 991–999, 2018PubMed
SakaguchiY, HamanoT, WadaA, HoshinoJ, MasakaneI: Magnesium and risk of hip fracture among patients undergoing hemodialysis. J Am Soc Nephrol29: 991–999, 2018PubMed10.1681/ASN.2017080849)| false
CovicA, Passlick-DeetjenJ, KroczakM, Büschges-SeraphinB, GhenuA, PonceP,
et al.
: A comparison of calcium acetate/magnesium carbonate and sevelamer-hydrochloride effects on fibroblast growth factor-23 and bone markers: Post hoc evaluation from a controlled, randomized study. Nephrol Dial Transplant28: 2383–2392, 2013PubMed
CovicA, Passlick-DeetjenJ, KroczakM, Büschges-SeraphinB, GhenuA, PonceP, : A comparison of calcium acetate/magnesium carbonate and sevelamer-hydrochloride effects on fibroblast growth factor-23 and bone markers: Post hoc evaluation from a controlled, randomized study. Nephrol Dial Transplant28: 2383–2392, 2013PubMed10.1093/ndt/gft203)| false
SahotaO, MundeyMK, SanP, GodberIM, HoskingDJ: Vitamin D insufficiency and the blunted PTH response in established osteoporosis: the role of magnesium deficiency. Osteoporos Int17: 1013–1021, 2006PubMed
SahotaO, MundeyMK, SanP, GodberIM, HoskingDJ: Vitamin D insufficiency and the blunted PTH response in established osteoporosis: the role of magnesium deficiency. Osteoporos Int17: 1013–1021, 2006PubMed10.1007/s00198-006-0084-3)| false
SakaguchiY, FujiiN, ShojiT, HayashiT, RakugiH, IsakaY: Hypomagnesemia is a significant predictor of cardiovascular and non-cardiovascular mortality in patients undergoing hemodialysis. Kidney Int85: 174–181, 2014PubMed
SakaguchiY, FujiiN, ShojiT, HayashiT, RakugiH, IsakaY: Hypomagnesemia is a significant predictor of cardiovascular and non-cardiovascular mortality in patients undergoing hemodialysis. Kidney Int85: 174–181, 2014PubMed10.1038/ki.2013.327)| false
de Roij van ZuijdewijnCL, GrootemanMP, BotsML, BlankestijnPJ, SteppanS, BüchelJ,
et al.
: Serum magnesium and sudden death in European hemodialysis patients. PLoS One10: e0143104, 2015PubMed
de Roij van ZuijdewijnCL, GrootemanMP, BotsML, BlankestijnPJ, SteppanS, BüchelJ, : Serum magnesium and sudden death in European hemodialysis patients. PLoS One10: e0143104, 2015PubMed10.1371/journal.pone.0143104)| false
XiongJ, HeT, WangM, NieL, ZhangY, WangY,
et al.
: Serum magnesium, mortality, and cardiovascular disease in chronic kidney disease and end-stage renal disease patients: A systematic review and meta-analysis. J Nephrol32: 791–802, 2019PubMed
TsujiH, VendittiFJJr, EvansJC, LarsonMG, LevyD: The associations of levels of serum potassium and magnesium with ventricular premature complexes (the Framingham Heart Study). Am J Cardiol74: 232–235, 1994PubMed
TsujiH, VendittiFJJr, EvansJC, LarsonMG, LevyD: The associations of levels of serum potassium and magnesium with ventricular premature complexes (the Framingham Heart Study). Am J Cardiol74: 232–235, 1994PubMed10.1016/0002-9149(94)90362-X)| false
MisialekJR, LopezFL, LutseyPL, HuxleyRR, PeacockJM, ChenLY,
et al.
: Serum and dietary magnesium and incidence of atrial fibrillation in whites and in African Americans: Atherosclerosis Risk in Communities (ARIC) study. Circ J77: 323–329, 2013PubMed
MisialekJR, LopezFL, LutseyPL, HuxleyRR, PeacockJM, ChenLY, : Serum and dietary magnesium and incidence of atrial fibrillation in whites and in African Americans: Atherosclerosis Risk in Communities (ARIC) study. Circ J77: 323–329, 2013PubMed10.1253/circj.CJ-12-0886)| false
PeetersMJ, van den BrandJA, van ZuilenAD, KosterY, BotsML, VervloetMG,
et al.
.; MASTERPLAN Study Group: Abdominal aortic calcification in patients with CKD. J Nephrol30: 109–118, 2017PubMed
PeetersMJ, van den BrandJA, van ZuilenAD, KosterY, BotsML, VervloetMG, .; MASTERPLAN Study Group: Abdominal aortic calcification in patients with CKD. J Nephrol30: 109–118, 2017PubMed10.1007/s40620-015-0260-7)| false
SigristMK, TaalMW, BungayP, McIntyreCW: Progressive vascular calcification over 2 years is associated with arterial stiffening and increased mortality in patients with stages 4 and 5 chronic kidney disease. Clin J Am Soc Nephrol2: 1241–1248, 2007PubMed
SigristMK, TaalMW, BungayP, McIntyreCW: Progressive vascular calcification over 2 years is associated with arterial stiffening and increased mortality in patients with stages 4 and 5 chronic kidney disease. Clin J Am Soc Nephrol2: 1241–1248, 2007PubMed10.2215/CJN.02190507)| false
InoueH, ShimizuS, WatanabeK, KamiyamaY, ShimaH, NakaseA,
et al.
: Impact of trajectories of abdominal aortic calcification over 2 years on subsequent mortality: A 10-year longitudinal study. Nephrol Dial Transplant33: 676–683, 2018PubMed
InoueH, ShimizuS, WatanabeK, KamiyamaY, ShimaH, NakaseA, : Impact of trajectories of abdominal aortic calcification over 2 years on subsequent mortality: A 10-year longitudinal study. Nephrol Dial Transplant33: 676–683, 2018PubMed10.1093/ndt/gfx253)| false
VervloetM, CozzolinoM: Vascular calcification in chronic kidney disease: Different bricks in the wall?Kidney Int91: 808–817, 2017PubMed10.1016/j.kint.2016.09.024)| false
Ter BraakeAD, TinnemansPT, ShanahanCM, HoenderopJGJ, de BaaijJHF: Magnesium prevents vascular calcification in vitro by inhibition of hydroxyapatite crystal formation. Sci Rep8: 2069, 2018PubMed
Ter BraakeAD, TinnemansPT, ShanahanCM, HoenderopJGJ, de BaaijJHF: Magnesium prevents vascular calcification in vitro by inhibition of hydroxyapatite crystal formation. Sci Rep8: 2069, 2018PubMed10.1038/s41598-018-20241-3)| false
PaschA, FareseS, GräberS, WaldJ, RichteringW, FloegeJ,
et al.
: Nanoparticle-based test measures overall propensity for calcification in serum. J Am Soc Nephrol23: 1744–1752, 2012PubMed
KeyzerCA, de BorstMH, van den BergE, Jahnen-DechentW, ArampatzisS, FareseS,
et al.
: Calcification propensity and survival among renal transplant recipients. J Am Soc Nephrol27: 239–248, 2016PubMed
KeyzerCA, de BorstMH, van den BergE, Jahnen-DechentW, ArampatzisS, FareseS, : Calcification propensity and survival among renal transplant recipients. J Am Soc Nephrol27: 239–248, 2016PubMed10.1681/ASN.2014070670)| false
BundyJD, CaiX, MehtaRC, SciallaJJ, de BoerIH, HsuCY,
et al.
.; CRIC Study Investigators: Serum calcification propensity and clinical events in CKD. Clin J Am Soc Nephrol14: 1562–1571, 2019PubMed
EelderinkC, Te Velde-KeyzerCA, FrenayAS,
et al.
. Serum calcification propensity and the risk of cardiovascular and all-cause mortality in the general population: The PREVEND study. Arterioscler Thromb Vasc Biol40:1942–1951, 2020
EelderinkC, Te Velde-KeyzerCA, FrenayAS, . Serum calcification propensity and the risk of cardiovascular and all-cause mortality in the general population: The PREVEND study. Arterioscler Thromb Vasc Biol40:1942–1951, 202010.1161/ATVBAHA.120.314187)| false
SakaguchiY, HamanoT, ObiY, MondenC, OkaT, YamaguchiS,
et al.
: A randomized trial of magnesium oxide and oral carbon adsorbent for coronary artery calcification in predialysis CKD. J Am Soc Nephrol30: 1073–1085, 2019PubMed
LeendersNHJ, van IttersumFJ, HoekstraT, HoenderopJGJ, VervloetMG: Routine hemodialysis induces a decline in plasma magnesium concentration in most patients: A prospective observational cohort study. Sci Rep8: 10256, 2018PubMed
LeendersNHJ, van IttersumFJ, HoekstraT, HoenderopJGJ, VervloetMG: Routine hemodialysis induces a decline in plasma magnesium concentration in most patients: A prospective observational cohort study. Sci Rep8: 10256, 2018PubMed10.1038/s41598-018-28629-x)| false
BressendorffI, HansenD, SchouM, PaschA, BrandiL: The effect of increasing dialysate magnesium on serum calcification propensity in subjects with end stage kidney disease: A randomized, controlled clinical trial. Clin J Am Soc Nephrol13: 1373–1380, 2018PubMed
BressendorffI, HansenD, SchouM, PaschA, BrandiL: The effect of increasing dialysate magnesium on serum calcification propensity in subjects with end stage kidney disease: A randomized, controlled clinical trial. Clin J Am Soc Nephrol13: 1373–1380, 2018PubMed10.2215/CJN.13921217)| false
VervloetMG, van BallegooijenAJ: Prevention and treatment of hyperphosphatemia in chronic kidney disease. Kidney Int93: 1060–1072, 2018PubMed10.1016/j.kint.2017.11.036)| false
